Dr. Reddy's Laboratories Limited
RDY
Price:
$14.2
Market Cap:
$999.69B
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for f...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2001-04-11
Stock Exchange
NYSE
Ticker
RDY
PE Ratio
[18.21]
ROE
[18.58%]
Current Ratio
[1.92]
Dividend Yield
[3.37%]
Enterprise Value
[1.04T]
Dividend History
The PE Ratio as of November 2024 (TTM) for Dr. Reddy's Laboratories Limited (RDY) is 18.21
According to Dr. Reddy's Laboratories Limited’s latest financial reports and current stock price. The company's current PE Ratio is 18.21. This represents a change of 547.46% compared to the average of 2.81 of the last 4 quarters.
Dr. Reddy's Laboratories Limited (RDY) Historical PE Ratio (quarterly & annually)
How has RDY PE Ratio performed in the past?
The mean historical PE Ratio of Dr. Reddy's Laboratories Limited over the last ten years is 5.68. The current 18.21 PE Ratio has changed 31.98% with respect to the historical average. Over the past ten years (40 quarters), RDY's PE Ratio was at its highest in in the December 2020 quarter at 218.80. The PE Ratio was at its lowest in in the December 2019 quarter at -4.21.
Average
5.68
Median
5.32
Minimum
3.45
Maximum
8.64
Dr. Reddy's Laboratories Limited (RDY) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Dr. Reddy's Laboratories Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 67.24%
Maximum Annual PE Ratio = 8.64
Minimum Annual Increase = -42.16%
Minimum Annual PE Ratio = 3.45
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 3.69 | 7.06% |
| 2023 | 3.45 | -42.16% |
| 2022 | 5.96 | -31.04% |
| 2021 | 8.64 | 67.24% |
| 2020 | 5.17 | 4.30% |
| 2019 | 4.95 | -30.56% |
| 2018 | 7.13 | -0.95% |
| 2017 | 7.20 | 41.17% |
| 2016 | 5.10 | -6.63% |
| 2015 | 5.46 | 31.39% |
Dr. Reddy's Laboratories Limited (RDY) Average PE Ratio
How has RDY PE Ratio performed in the past?
The current PE Ratio of Dr. Reddy's Laboratories Limited (RDY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
4.37
5-year avg
5.38
10-year avg
5.68
Dr. Reddy's Laboratories Limited (RDY) PE Ratio vs. Peers
How is RDY’s PE Ratio compared to its peers?
Dr. Reddy's Laboratories Limited’s PE Ratio is greater than Pacira BioSciences, Inc. (-8.92), less than Phibro Animal Health Corporation (55.24), greater than Collegium Pharmaceutical, Inc. (10.91), greater than Silver Spike Investment Corp. (13.39), greater than ANI Pharmaceuticals, Inc. (-155.73), greater than Alkermes plc (14.10), greater than Intra-Cellular Therapies, Inc. (-104.94), greater than Eagle Pharmaceuticals, Inc. (0.34), less than Prestige Consumer Healthcare Inc. (20.46), greater than Evotec SE (-4.46), less than Supernus Pharmaceuticals, Inc. (33.45), greater than Deciphera Pharmaceuticals, Inc. (-11.74),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.92 | $810.34M | |
| 55.24 | $961.56M | |
| 10.91 | $966.22M | |
| 13.39 | $66.72M | |
| -155.73 | $1.20B | |
| 14.10 | $4.66B | |
| -104.94 | $9.08B | |
| 0.34 | $12.31M | |
| 20.46 | $4.19B | |
| -4.46 | $1.59B | |
| 33.45 | $2.00B | |
| -11.74 | $2.21B |
Build a custom stock screener for Dr. Reddy's Laboratories Limited (RDY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dr. Reddy's Laboratories Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Dr. Reddy's Laboratories Limited (RDY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Dr. Reddy's Laboratories Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Dr. Reddy's Laboratories Limited's PE Ratio?
How is the PE Ratio calculated for Dr. Reddy's Laboratories Limited (RDY)?
What is the highest PE Ratio for Dr. Reddy's Laboratories Limited (RDY)?
What is the 3-year average PE Ratio for Dr. Reddy's Laboratories Limited (RDY)?
What is the 5-year average PE Ratio for Dr. Reddy's Laboratories Limited (RDY)?
How does the current PE Ratio for Dr. Reddy's Laboratories Limited (RDY) compare to its historical average?